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Comparative effectiveness research (CER) aims to provide decision makers with the evidence needed to evalu-
ate the benefits and harms of alternative clinical management strategies. CER has become a national priority,
with considerable new research funding allocated. Cardiovascular disease is a priority area for CER. This work-
shop report provides an overview of CER methods, with an emphasis on practical clinical trials and observational
treatment comparisons. The report also details recommendations to the National Heart, Lung, and Blood Insti-
tute for a new framework for evidence development to foster cardiovascular CER, and specific studies to ad-
dress 8 clinical issues identified by the Institute of Medicine as high priorities for cardiovascular CER.
(J Am Coll Cardiol 2012;60:569–80) © 2012 by the American College of Cardiology Foundation
ublished by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2011.12.057Comparative effectiveness research (CER) has recently
emerged as a national priority, spurred by healthcare reform
and economic stimulus legislation. Congress appropriated
$1.1 billion for CER as part of the American Recovery and
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6, 2011, accepted December 20, 2011.Reinvestment Act of 2009 and is anticipated to enable
additional annual spending of $500 million as part of the
newly established Patient-Centered Outcomes Research
Institute. According to congressional legislation, the
Patient-Centered Outcomes Research Institute will give
priority for project management to the National Institutes
of Health and the Agency for Health Research and Quality.
Therefore, the National Heart, Lung, and Blood Institute
(NHLBI) may have new opportunities to advance CER
related to cardiovascular disease, which remains the leading
cause of death and disability in the United States today.
The NHLBI sponsors workshops to solicit input and
recommendations on important topics, so on July 13 and 14,
2010, the Division of Cardiovascular Sciences convened a
workshop on CER in cardiovascular disease. The workshop
brought together 25 outside experts from a variety of disci-
plines (clinical trials, epidemiology, biostatistics, health services
research, and clinical medicine) to discuss a range of future
opportunities that NHLBI could consider in CER as it relates
to cardiovascular disease and the specific priorities for CER in
cardiovascular disease that were identified by the Institute of
Medicine (IOM). The discussions at the workshop, therefore,
represent the opinions and recommendations of the partici-
pants and are not necessarily the policy or priorities of NHLBI.
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deliberations and recommenda-
tions to the NHLBI of this
workshop: “Future Directions for
Cardiovascular Disease Compar-
ative Effectiveness Research.”
The report is divided into several
sections, including: 1) an over-
view of CER data sources and
methods; 2) a proposed frame-
work for CER at the NHLBI
(Fig. 1); and 3) possible ap-
proaches to 8 priority CER top-
ics identified by the IOM in the
reas of cardiovascular and peripheral vascular disease.
verview of CER
omparative effectiveness research has been defined as “the
eneration and synthesis of evidence that compares the
enefits and harms of alternative methods to prevent,
iagnose, treat, and monitor a clinical condition or to
mprove the delivery of care. The purpose of CER is to
ssist consumers, clinicians, purchasers and policy makers in
aking informed decisions that will improve healthcare at
oth the individual and population levels” (1). CER can
ocus on care at the patient level or the system level, but
egardless of its scope, CER is intended to provide infor-
ation that can facilitate medical decision making and
mprove health outcomes (2).
Abbreviations
and Acronyms
CER  comparative
effectiveness research
CT  computed
tomography
IOM  Institute of
Medicine
NHLBI  National Heart,
Lung, and Blood Institute
RCT  randomized
controlled trial(s)
Figure 1 Conceptual Framework for CER
CER  comparative effectiveness research; CVD  cardiovascular disease; IOM There is great public value in rigorous studies comparing
lternative strategies for diagnosis and treatment, as dem-
nstrated by many landmark NHLBI-sponsored clinical
rials (3–13). Nevertheless, comparative effectiveness studies
hat would facilitate healthcare decisions are not performed
s often as they are needed, and gaps persist between the
roduction of scientific evidence and the needs of consum-
rs and healthcare providers for evidence on CER. Because
here are limited resources to support biomedical research, it
s necessary to prioritize key clinical questions that can be
nswered with comparative effectiveness studies, while ex-
anding as much as possible the pool of investigators
apable of performing CER.
tudy Designs for CER
variety of methods are used in CER, including random-
zed trials, observational studies, simulations and models,
ystematic reviews, meta-analyses, and collaborative pooling
f individual patient data from multiple studies. Random-
zed trials can be used to compare a management strategy
preventative, diagnostic, therapeutic) with the best alterna-
ive strategy. Analyses of data from clinical registries,
lectronic health records, and administrative databases can
ddress CER questions regarding situations in which ran-
omization may be difficult. Whereas observational studies
sing existing data may be simpler and less expensive to
onduct, they are more susceptible to bias introduced by
election of patients for alternative treatments. Statistical
pproaches to analysis of observational data can be used to
ute of Medicine.Instit
571JACC Vol. 60, No. 7, 2012 Hlatky et al.
August 14, 2012:569–80 Cardiovascular Comparative Effectiveness Researchminimize these biases, but these methods need to be further
developed. Decision models and simulations may also be
very useful methods in CER. The workshop participants
explored the unique opportunities, strengths, and limita-
tions of these methods for use in CER, as summarized
herein.
Randomized trials. Randomized clinical trials (RCT) may
be applied in CER to compare treatments (e.g., use of a
drug, device, procedure, or a behavioral intervention), clin-
ical evaluation strategies (e.g., biomarkers, imaging), health-
care delivery methods (e.g., disease management programs,
specialist vs. generalist care), and policy interventions (e.g.,
copayments, formulary restrictions, regionalization of pro-
cedures). The strengths of the RCT include its use of a
prospective protocol, standardized data collection, complete
follow-up, and random treatment assignment, each of
which enhances its “internal validity.” An RCT is particu-
larly appropriate when a high level of evidence is required to
change practice, such as when optimal management is
controversial, the effect of the treatment on outcomes is
modest, or the intervention is costly. Although RCT often
involve highly selected patients and atypical practice set-
tings, which can limit generalizability, RCT can be designed
to enroll more representative patient populations and can be
performed in more typical practice settings.
There are many practical barriers to conducting large,
representative clinical trials in the United States. The focus
on delivering care efficiently and uniformly may not readily
accommodate clinical research in routine clinical practice.
Building the infrastructure to perform multicenter clinical
trials can be difficult, time-consuming, and costly. Thus,
exploring strategies to promote more efficient clinical trials
is important, such as adopting “large practical trial designs”
or fostering the conduct of a range of CER trials by existing
investigator or site teams. Use of real-world settings, such as
private practice groups, community health centers, and
integrated healthcare systems, may enhance recruitment of
representative patients in CER trials.
Monetary barriers can impede the conduct of clinical
trials, because the cost of research data collection, clinic
visits and tests, and follow-up is high. Thus, identifying
ways to streamline data collection while maintaining accu-
racy and validity over the length of follow-up would
enhance the ability to conduct CER trials. Health insurers
may balk at covering the costs of clinic visits and tests for
patients in a clinical trial, which increases the cost to the
research budget and may lead patients to drop out of the
study. Furthermore, in some instances, financial incentives
in healthcare may not be aligned for randomized trials; for
example, trials that randomize patients to procedures com-
pared with medical therapy may result in foregone proce-
dural fees. The duration of follow-up in clinical trials is also
constrained by cost, which limits collection of long-term
data on comparative efficacy and safety.
Barriers for CER trials also include lack of time in busy
practices to enroll participants in research studies and lowlevels of academic recognition for site investigators who are
just 1 member of a large trial team. Whereas institutional
review boards are needed to protect participants in clinical
trials, the multiplicity of jurisdictions across multisite trials
complicates the conduct of the trial. Centralized or simpli-
fied institutional review processes for multicenter studies
should be explored, particularly for comparative trials of
existing, approved interventions.
Clinical registries. A clinical registry is the prospective
collection of standardized data on the clinical characteristics
and outcomes of patients defined by a particular disease,
diagnosis, procedure, or exposure. Clinical registries share
some features with randomized trials, such as standardized
data collection, but unlike clinical trials, they do not dictate
patient treatment by either random assignment or a strict
protocol. Clinical registries can have broader inclusion
criteria than clinical trials do, and, therefore, they may better
represent the diversity of patients, providers, and practice
settings found in contemporary clinical care. Clinical regis-
tries occupy a middle ground between the formal structure
of a randomized trial and the collection of relatively un-
structured data from medical charts, electronic health re-
cords, or claims data.
Clinical registries have evolved from small case series to
national (or international) collaborations that enroll thou-
sands to millions of patients. Standardized data definitions
and data collection methods are key features of a high-
quality clinical registry, as they ensure comparable levels of
details about each patient enrolled. Documenting out-
comes—particularly outcomes that occur late after a single
episode of care—is also essential if clinical registries are to
be used in CER. Longer follow-up can be obtained actively
by contacting patients (as is done in clinical trials) or
passively by linking registry data to electronic health re-
cords, claims data, or state and national mortality files.
Clinical registries have been used to define contemporary
practice patterns, document disparities in care, and assess
the safety of cardiovascular drugs, devices, and procedures in
clinical practice. Clinical registries can also be analyzed to
compare alternative treatments, but these studies require
advanced biostatistical methods to reduce the biases intro-
duced by nonrandomized patient selection for treatment.
Clinical registries may also be linked with randomized
clinical trials, as when a registry prospectively collects data
on patients screened for entry into a trial or on patients
eligible for a trial who decline to be randomized (14).
Randomized trials can also capitalize on an ongoing clinical
registry, which can be used to identify eligible patients and
capture clinical data. Hybrid registry trial designs may be
particularly powerful tools for CER, as they permit efficient
patient enrollment and provide information of the general-
izability of trial results.
The resources required to establish and maintain clinical
registries have been provided by a variety of mechanisms.
Professional societies have sponsored notable clinical regis-
tries often supported by hospital-paid fees for participation,
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Guidelines Programs (in cardiovascular disease, heart fail-
ure, and stroke), the Society of Thoracic Surgeon’s National
Cardiothoracic Surgery databases (covering coronary bypass
surgery, valve surgery, thoracic surgery, and congenital heart
surgery), and the American College of Cardiology’s Na-
tional Cardiovascular Data Registries (including percutane-
ous coronary intervention, implantable defibrillators, and
carotid stenting, as well as diseases such as congenital
cardiovascular disease and acute coronary syndromes). State
governments have also sponsored clinical registries, such as
the New York State Registry for cardiac surgery and
percutaneous coronary intervention. Clinical registries have
also been established using federal research funding (e.g.,
the NHLBI-sponsored Dynamic Registry). Industry has
sponsored clinical registries on particular drugs or devices
(e.g., stent registries), as well as specific diseases (e.g., the
NRMI [National Registry of Myocardial Infarction], the
ADHERE [Acute Decompensated Heart Failure National]
registry, and the REACH [Reduction of Atherothrombosis
for Continued Health] registry).
Health system data. Electronic health records and the
administrative records of insurers or integrated health plans
are valuable sources of observational data for CER. These
“found data” are generated in the routine practice of medical
care for billing purposes, public reporting, or clinical care and
are not produced primarily for research purposes. For instance,
the diagnoses and procedures during hospitalization are re-
corded using the nomenclature of the International Classifica-
tion of Diseases, Clinical Modification (ICD-9-CM) and
reported to public authorities and health insurers. These
administrative data are not subject to the standardization
and quality control applied to clinical trial or clinical registry
data, although these data are usually recorded by trained
medical records abstractors and required for provider reim-
bursement. Some integrated healthcare organizations have
additional sources of clinical data, such as drug prescrip-
tions, outpatient claims, and computerized laboratory re-
sults. Linkage of several of these data sources can give a very
detailed picture of medical care provided to a representative,
relatively unselected population of patients.
The advent of fully electronic health records offers the
possibility of capturing greatly detailed clinical information
about individual patients, such as symptoms, vital signs, and
results of imaging studies. There are formidable technical
challenges in extracting specific data elements from elec-
tronic health records, because clinical notes are typically
entered as free text rather than using a controlled vocabu-
lary. Advances in medical informatics, such as studies on
natural language processing, will likely facilitate the use of
electronic health records for research purposes. Neverthe-
less, the use of electronic records for research purposes does
not overcome the well-recognized fundamental limitations
of retrospective chart review studies: namely, that key data
may not have been recorded at all; and that the data thatwere recorded are unlikely to be standardized or quality
controlled.
Analysis of observational data. A weakness of all obser-
vational CER studies (including analyses of clinical regis-
tries, electronic health records, and administrative data) is
the absence of randomized assignment of treatments. In
contrast to a randomized trial, clinicians and patients
represented in observational databases select treatments for
a variety of reasons, which may not be recorded in the chart.
Treatment selection can lead to differences in patient
prognosis between treatment groups, so their subsequent
clinical outcomes may differ, even in the absence of a
treatment effect. Methods for addressing selection biases,
whether due to known or unknown factors, are evolving.
One simple step is to restrict the study patient population to
newly treated patients and to patients eligible for either
treatment; these restrictions narrow any pre-treatment dif-
ferences between patients receiving alternative therapies
(15). Modeling the selection of treatment by using a
propensity score or a disease risk score can balance treat-
ment groups on large numbers of measured clinical covari-
ates (16,17). Marginal structural models with inverse
weighting by propensity for treatment have been used to
estimate the effect on outcomes of treatments that vary over
time, such as use of prescription drugs (18). Each of these
statistical methods relies on adjusting for clinical character-
istics that were recorded in the data and, therefore, may not
adjust fully for clinical factors that were not recorded (e.g.,
patient frailty or socioeconomic status) or that are difficult to
capture (e.g., degree of social support). Instrumental vari-
able methods and multilevel analyses have been used in an
attempt to adjust for unmeasured confounders (19–21).
These approaches identify variables that are strongly related
to the likelihood of receiving a specific treatment, but do not
directly affect clinical outcomes (e.g., inclusion of specific
drugs in a formulary, distance to a referral hospital). The
workshop participants recognized the need for further
advances in statistical methods in order to conduct high-
quality CER that minimizes confounding and residual
selection bias in observational treatment comparisons.
Systematic reviews and decision models. Systematic re-
views and meta-analyses of existing effectiveness and safety
data are an important tool for CER. Systematic reviews can
identify evidence gaps, including a lack of evidence or
unclear evidence for an important clinical question, which
suggest a new trial is warranted (22) and when there is “too
much evidence,” which suggests further trials may be
unnecessary (23). Network meta-analysis (mixed treatment
comparison meta-analysis) may be used to compare inter-
ventions even when direct “head-to-head” trials are not
available (24). This new statistical approach is promising,
but it is still being examined for its validity as a method to
compare treatments.
The potential for treatment efficacy to vary significantly
according to patient characteristics (e.g., age, sex, diabetes,
or genetic markers) is an important dimension of CER, as
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Very large sample sizes are required to investigate potential
variation in treatment effects across populations, which can
be accomplished by pooling individual patient-level data
from several trials. Further research could address the
practical and methodologic challenges of collaborative stud-
ies that pool data from multiple studies of cardiovascular
treatments.
Decision models and simulation studies are also valuable
methods to foster CER. These techniques start with the
best available evidence on a clinical question and typically
rely on the results of systematic reviews, meta-analyses, and
pooling studies to provide the needed data. Models and
simulation studies are particularly well suited to identify
evidence gaps and the value of information by pinpointing
which clinical factors have the greatest impact on the clinical
effectiveness and cost-effectiveness of treatment alternatives.
Studies can subsequently be designed to address the most
important evidence gaps, which will be particularly valuable
in meeting the CER objective of “comparing benefits and
harms of alternative methods [of care].”
Proposed Framework for CER
The workshop participants proposed a new framework for
evidence development (Fig. 1) to foster cardiovascular CER.
This framework identifies gaps between the evidence
needed for practice and the research available to support it.
A “portfolio analysis” of the current state of knowledge, by
using clinical guidelines, evidence reviews, and decision
models to identify key evidence gaps, could focus CER on
key questions through a variety of research designs, includ-
ing observational studies, clinical registries, and randomized
trials. This cycle of portfolio analysis, identification of key
evidence gaps, and research addressing these gaps could
repeat over time (Table 1).
The proposed framework (Fig. 1) involves a multiple
stakeholder process to identify questions for CER and is
consistent with recent changes on the political as well as
scientific landscape. For example, the creation of the new
Patient-Centered Outcomes Research Institute suggests
that the model for setting research priorities may be chang-
ing from an investigator and industry driven process to one
with broader patient and clinician input.
General Recommendations toFoster Comparative Effectiveness ResearchTable 1 General Recommendations toFoster Comparative Effectiveness Research
Conduct portfolio analyses in key clinical areas
Identify knowledge gaps
Strengthen relationships among stakeholders
Leverage the strength of different research methods: trials, registries,
simulations, evidence synthesis
Advance analytic methods for comparative effectiveness research
Promote knowledge discovery as part of clinical practiceFoster training and careers in comparative effectiveness researchThe proposed framework implies that knowledge gaps
could be identified through systematic reviews of existing
evidence, meta-analyses, and decision analytic models.
These types of studies could be efficient and timely oppor-
tunities to focus on important comparative effectiveness
studies (Table 1).
The proposed framework also implies that interactions
among potential funders and stakeholders, such as the
Agency for Healthcare Research and Quality, the Centers
for Medicare and Medicaid Services, and the Centers for
Disease Control and Prevention could help foster CER
focused on cardiovascular disease. The Cochrane Collabo-
ration is an international organization that conducts system-
atic reviews and promotes methodologic development, and
it could assist in assessing evidence gaps and areas of focus
for research. The professional societies (e.g., the American
College of Cardiology, the American Heart Association,
and the Society of Thoracic Surgeons) now operate clinical
registries that may be well suited to cardiovascular CER,
and they develop clinical guidelines, performance measures,
and appropriate-use criteria that could potentially translate
CER findings into practice.
Expand the scope of discovery. CER focuses on develop-
ing scientific knowledge that will be useful during the course
of patient care. The creativity and innovation that charac-
terize investigator-initiated research have served medical
science well. However, because the research questions of
CER focus on addressing the needs of practitioners and
patients, the scope of discovery may need to expand to
include not only specific topics of interest to individual
investigators and experts, but also topics driven by clinical
evidence gaps.
The implications of developing a CER portfolio that
focuses on knowledge gaps are far reaching. The evolution
of a research question from model to meta-analysis to
mega-trial to implementation underscores the contributions
of methodologic research as well as research on specific
clinical questions. Whereas some clinical questions may be
addressed in large randomized clinical trials, other pivotal
questions may not be amenable to randomized studies and,
therefore, require alternative methods.
Create a culture of research. The broad scope of CER
implies similar breadth in thinking about the research
enterprise, such that the development of new knowledge
about optimal practice becomes an intrinsic part of the
healthcare system. Because CER aims to address patient
and provider needs, health systems, providers, and patients
should embrace the need to perform CER and recognize its
value. A culture of research may be fostered when it is
recognized that there is uncertainty regarding what consti-
tutes optimal care, so that alternative forms of management
may be reasonable and acceptable—the concept of clinical
equipoise. While clinical systems and caregivers face chal-
lenges incorporating research as part of daily practice, they
should recognize that improving the quality of care through
discovery and learning from experience should be part of
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research into routine care might be further fostered by
focusing on quality improvement, aligning incentives within
health systems, and, in the larger healthcare enterprise, by
establishing policies such as coverage with evidence devel-
opment and pay for performance.
The collection of observational data as part of a prospec-
tive clinical registry is an example of how research can be
incorporated into daily practice. Clinical registries cover
only specific clinical populations, however, and a broader
knowledge base could advance CER. Fully interoperable
electronic health records, with promotion of standardized
clinical terminology, would facilitate CER, particularly if
electronic health records, clinical registries, image reposito-
ries, clinical trial data, and longitudinal claims can be linked
to create study cohorts. To this end, further development of
health informatics and its application to cardiovascular
disease is an opportunity to advance CER.
Nurture the national CER workforce. Individuals from
many distinct backgrounds are needed to meet the chal-
lenges of CER, ranging from skilled investigators to inquis-
itive clinicians, knowledgeable patients, and practical meth-
odologists. Thus, “team science” is integral to the success of
CER. Paralleling the need for more diverse research part-
ners is the opportunity to collaborate with nontraditional
research venues and partners, including those usually fo-
cused only on care delivery or education, rather than
scholarly research.
As CER is relatively new field, there is a great need for
more investigators who are well trained in its methods.
Training, mentoring, and professional development pro-
grams aimed specifically at expanding the pool of investi-
gators skilled in the methods of cardiovascular CER are
possible ways to cultivate this field. Furthermore, nontradi-
tional stakeholders may be valuable contributors to the
development of the portfolio of CER studies.
Institute of Medicine Priorities
The workshop addressed 2 broad questions. 1) How might
the NHLBI foster CER related to cardiovascular disease in
general? 2) How might the NHLBI respond to the specific
CER priorities in the area of cardiovascular disease identi-
fied by the IOM? In this section, we summarize the
workshop participants’ recommendations on the second
broad question—what types of studies could potentially
address the IOM priorities (1)? The workshop participants
were charged to identify examples of 1 or 2 study ideas for
each IOM area.
NHLBI convenes working groups of experts to provide
recommendations and input on specific topic areas, which
the Institute then carefully reviews. The suggestions of this
workshop represent a list of important areas for investigator-
initiated and/or Institute-initiated projects. The Institute care-
fully considers these and other recommendations as it sets its
priorities and attempts to maintain a balanced portfolio acrossits entire mission; no NHLBI funding commitment is made or
implied by inclusion of the topics in the report of this
workshop. The workshop recognized that the NHLBI is
particularly able to organize CER studies free of conflicts of
interest related to specific drugs, devices, or management
strategies and has great experience in conducting comparative
studies of alternative management strategies to treat cardiovas-
cular disease.
The IOM priority areas discussed at the workshop
include:
• Compare the effectiveness of treatment strategies for
atrial fibrillation including surgery, catheter ablation,
and pharmacologic treatment;
• Compare the effectiveness of anticoagulant therapies
(e.g., low-intensity warfarin, aspirin, injectable anti-
coagulants) for patients undergoing procedures;
• Compare the effectiveness of treatment strategies for
vascular claudication (e.g., medical optimization, smok-
ing cessation, exercise, catheter-based treatment, open
surgical bypass);
• Compare the effectiveness of aggressive medical man-
agement and percutaneous coronary interventions in
treating stable coronary disease for patients of differ-
ent ages and with different comorbidities;
• Compare the effectiveness of innovative treatment strat-
egies (e.g., cardiac resynchronization, remote physiologic
monitoring, pharmacologic treatment, novel agents such
as CRF-2 receptors) for congestive heart failure;
• Compare the effectiveness of different treatment strat-
egies (e.g., modifying target levels for glucose, lipid, or
blood pressure) in reducing cardiovascular complica-
tions in newly diagnosed adolescents and adults with
type 2 diabetes;
• Compare the effectiveness of traditional risk stratifica-
tion for coronary heart disease and noninvasive imaging
(using coronary artery calcium, carotid intima media
thickness, and other approaches) on outcomes; and
• Compare the effectiveness of computed tomography
(CT) angiography and conventional angiography in
assessing coronary stenosis in patients at moderate
pre-test risk of coronary artery disease.
Atrial Fibrillation
Atrial fibrillation is a highly prevalent condition associated
with increased cardiovascular mortality and a high risk of
stroke. The NHLBI has previously supported comparative
treatment trials for atrial fibrillation, including the completed
AFFIRM (Atrial Fibrillation Follow-Up Investigation of
Rhythm Management) trial (4) and the ongoing CABANA
(Catheter Ablation Versus Antiarrhythmic Drug Therapy for
Atrial Fibrillation) trial (NCT00911508). The NHLBI is also
funding a clinical registry of atrial fibrillation in 2 large
integrated health plans to address specific comparative
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atrial fibrillation registry (25) and epidemiologic studies of
atrial fibrillation. Despite these and other studies of atrial
fibrillation, key knowledge gaps remain, including: 1) the
generalizability of trials to the larger population of patients
with atrial fibrillation; 2) whether the treatment approach
ought to vary depending on the subtype of atrial fibrillation;
and 3) the effect of treatments on expanded outcomes, such
as stroke, dementia, heart failure, quality of life, healthcare
utilization, and cost-effectiveness.
The workshop participants recommend that 1 approach
to fill these gaps could be a robust clinical registry with
broader representation of patients with atrial fibrillation,
with a particular focus on patients with new onset disease, to
better define risks for adverse outcomes in relation to patient
characteristics, subtype of atrial fibrillation, biomarkers, and
treatment. In conjunction with the registry, a comprehen-
sive decision model of atrial fibrillation management, as
outlined in Figure 2, could be used to identify priority areas
for additional CER studies, including clinical trials. There is
also the potential to build on ongoing studies of other
conditions and treatments by adding atrial fibrillation as a
secondary outcome measure.
Anticoagulant Therapies
Anticoagulant and antithrombotic therapies are increasingly
used to prevent thromboembolism in patients with atrial
fibrillation, deep vein thrombosis, or pulmonary embolism.
Management of these therapies at the time of invasive
Figure 2 AF CER Evidence and Data Portfolio Management
The general framework for CER (see Fig. 1) is applied to atrial fibrillation (AF). Exa
screened but not randomized to a clinical trial, or individuals followed after comple
ter Ablation Versus Anti-Arrhythmic Drug Therapy for Atrial Fibrillation Trial) (NCT00
SES  socioeconomic status; other abbreviations as in Figure 1.procedures and surgery poses a difficult problem in balanc-
ing the bleeding risk due to treatment and the thromboem-
bolic risk due to the underlying disease (26). Furthermore,
immobilization after surgery promotes venous thromboem-
bolism, which is particularly increased by hip or knee joint
replacement procedures. Management decisions have been
further complicated by the introduction of several novel
anticoagulant drugs that lack specific antidotes and whose
anticoagulant intensity cannot be reliably assessed by labo-
ratory tests. The NHLBI is currently supporting the
BRIDGE (Effectiveness of Bridging Anticoagulation for
Surgery) trial (NCT00786474), and the GIFT (Genetics
Informatics Trial of Warfarin to Prevent DVT) trial
(NCT01006733), which tests low-intensity warfarin prop-
erties following orthopedic surgery.
The workshop participants felt that a large “real-world”
registry of patients undergoing specific surgical procedures
would be of benefit to document risk factors for bleeding,
cardiac events, and thromboembolism. This registry could
be used to assess the effect of different treatments on those
outcomes, particularly among patients under-represented in
randomized trials (Online Fig. 1). Assessment of adverse
orthopedic outcomes such as joint hemorrhage, peripros-
thetic infection, and repeat procedures would provide crit-
ical information needed to balance risks and benefits of
anticoagulant treatment. The registry could capitalize on
substantial practice variations to perform observational
treatment comparisons and assess the effects of treatment on
cost, quality of life, and cost-effectiveness.
of registries might include an AF clinical care registry, registry of individuals
f a clinical trial. An example of an ongoing AF clinical trial is the CABANA (Cathe-
8). AFl  atrial flutter; CHF  congestive heart failure; QOL  quality of life;mples
tion o
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Lower extremity peripheral artery disease is a common,
costly condition that is associated with high morbidity and
mortality. The pathophysiology of exertional limb claudica-
tion is analogous to that of exertional angina pectoris, but
claudication has not received as much attention as angina in
either clinical investigation or the development of new drugs
and devices. There have been relatively few CER studies of
claudication treatments, apart from the ongoing NHLBI-
sponsored CLEVER (Claudication: Exercise Versus Endo-
luminal Revascularization) trial (NCT00132743). CLEVER
compares exercise therapy with endovascular stenting for
treatment of a documented lesion in a specific proximal
aortoiliac site that is amenable to stent therapy (27).
CLEVER does not, however, address the larger question of
whether a strategy of mechanical limb revascularization
(using any combination of endovascular techniques and
surgery) leads to better clinical outcomes than the alterna-
tive strategy of optimal medical management (including
exercise, lifestyle modification, and drug therapy). A large
practical randomized trial comparing these distinct ap-
proaches to claudication could address this priority area
(Online Fig. 2). This trial could enroll relatively unselected
patients with claudication, whether new onset or after prior
revascularization, without requiring prior angiography or
any specific anatomic findings. The major outcomes of this
trial could be patient functional capacity and quality of life,
with secondary outcomes of major clinical complications,
cardiovascular risk factor control, medical care utilization
and cost, and cost-effectiveness.
Severe limb ischemia, including acute or chronic critical
limb ischemia syndromes, represents another major clinical
manifestation of peripheral artery disease, in which tissue
necrosis is threatened due to reduced resting blood flow.
There are newer therapeutic options for severe limb isch-
emia, but few reliable data on their long-term clinical
outcomes or comparative effectiveness. Severe limb ischemia
is particularly suitable for the process of priority setting
outlined in Figure 1: performing a systematic review of
evidence; modeling to identify critical parameters; and
collecting observational data on epidemiology, treatment
patterns, and determinants of clinically important outcomes.
Establishment of a clinical registry of patients with severe
limb ischemia could foster CER on this topic by identifying
patient, provider, and treatment predictors of outcome.
Such a registry could provide the basis for initiating subse-
quent, targeted clinical trials of evaluation and management
strategies for severe limb ischemia.
Stable Ischemic Heart Disease
Coronary artery disease is well recognized as a major health
problem in the United States and has been the subject of
numerous clinical investigations. The NHLBI has spon-
sored pivotal CER clinical trials, including the CASS(Coronary Artery Surgery Study) (28) and BARI 2D
(Bypass Angioplasty Revascularization Investigation Two,
Diabetes) (NCT00006305) (7) to compare coronary revas-
cularization with medical therapy among patients with
ischemic heart disease. The NHLBI has also sponsored
trials comparing bypass surgery with coronary angioplasty
(BARI [29] and EAST [Emory Angioplasty Versus Surgery
Trial] [9]). Despite extensive investigation in this field,
numerous knowledge gaps persist about optimal manage-
ment of patients with stable ischemic heart disease. In
particular, prior clinical trials have required knowledge of
the coronary anatomy prior to randomization, but the
decision to perform an invasive coronary angiogram has
often been tantamount to the decision to perform coronary
revascularization. The NHLBI just announced funding for
the ISCHEMIA (International Study of Comparative
Health Effectiveness with Medical and Invasive Ap-
proaches), a trial that will randomize patients with stable
coronary disease and objective evidence of myocardial isch-
emia to an invasive strategy of early coronary angiography or
a conservative strategy of initial optimal medical therapy,
with angiography reserved for development of refractory
symptoms or a clinical event (Online Fig. 3), in order to
address a need for further evidence on this important
decision point.
In addition to a large practical trial of coronary revascu-
larization, many questions remain about how to define and
deliver optimal medical management for patients with stable
ischemic heart disease. In particular, it has been challenging
to promote drug adherence and behavior change (diet,
exercise, smoking cessation) in the setting of a busy outpa-
tient practice. One approach to consider is to apply insights
from behavioral economics to investigate the effect of
economic incentives to clinicians (e.g., structuring of pay-
ment) or patients (e.g., copayments for drugs or visits, the
costs of improving exercise and diet) on clinical outcomes.
As a third consideration, formal analysis of evidence gaps
and opportunities in stable ischemic heart disease using the
processes of evidence review, model building, and analysis of
clinical registries (Fig. 1) would allow the identification of
additional opportunities for CER in this area.
Heart Failure
Heart failure continues to be the most common reason for
hospital admission among Americans 65 years of age and
older, and the prevalence of heart failure has continued to
rise, even though other forms of heart disease have been
declining. The NHLBI has sponsored numerous CER inves-
tigations in heart failure, including the SOLVD (Studies of
Left Ventricular Dysfunction) trial (30), the SCD-HeFT
(Sudden Cardiac Death in Heart Failure) (NCT00000609)
trial (11), and, more recently, the STICH (Surgical Treatment
of Ischemic Heart Failure) (NCT00023595) trial (12). Many
other studies of the effects of drugs and devices on clinical
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industry.
A hallmark of heart failure is that many patients are
frequently rehospitalized to treat exacerbations of the dis-
ease, at great expense to the system and considerable distress
to patients and their families. There are major gaps in
knowledge about how to address this problem, so the
workshop participants proposed that 1 study to consider is
enhanced disease management and transition of care with
monitoring (remote or biomarker) as a means of improving
clinical outcomes. A large practical trial (Fig. 3) could enroll
unselected patients with heart failure at the time of hospital
discharge and randomize them either to usual care or to
enhanced disease management with tailored therapy guided
by remote monitoring (e.g., weight, heart rate, blood pres-
sure, biomarkers). An associated registry of patients with
heart failure could be established in conjunction with the
randomized trial to collect additional data on the full
spectrum of patients with heart failure and thereby assess
the generalizability of the trial results.
The proposed study could use a cluster randomized
design (31), in which clinical sites rather than individuals
are randomized. The cluster randomized design is well
suited to evaluation of interventions that target behavior or
processes of care. Cluster randomized trials are particularly
useful when it is difficult to conceal the nature of the
intervention from the clinic staff and to mask patients to the
intervention. The novel research designs that may be re-
quired for CER entail unique challenges (32). Despite such
challenges, the workshop participants encouraged use of
such novel research designs, as they provide several advan-
Figure 3 Proposed Cluster Randomized Trial for the Manageme
DC  discharge; DM  disease management; QOL  quality of life.tages, including simpler patient recruitment and “real-life”
data directly applicable to clinical practice.
Diabetes
The incidence of diabetes continues to rise, driven in large
part by the epidemic of obesity in the United States. Most
patients with diabetes die of heart disease, yet the optimal
approach to prevention and treatment of cardiovascular
disease in patients with diabetes is not well established.
Despite the recent publications of the results of the
ACCORD (Action to Control Cardiovascular Risk in
Diabetes Trial) (33), ADVANCE (Action in Diabetes and
Vascular Disease: Preterax and Diamicron Modified Re-
lease Controlled Evaluation) (34), VADT (Veterans Affairs
Diabetes) trial (35), long-term follow-up from UKPDS
(United Kingdom Prospective Diabetes Study) and Steno 2
Study (36), and the ongoing Look AHEAD (Action for
Health in Diabetes) trial (NCT00017953), the comparative
effectiveness of tight glycemic control versus more liberal
control of diabetes, of lifestyle management versus early
drug treatment, of different initial drug treatments, and of
different systems of care are all uncertain in patients with
newly diagnosed diabetes. The workshop participants felt
that the IOM priority could potentially be addressed by the
following 2 trials.
The first trial could compare 2 strategies for initial
treatment in patients with newly diagnosed type 2 diabetes:
intensive lifestyle intervention versus immediate metformin
(Online Fig. 4). A third arm of this trial could include both
interventions. A second trial could focus on the comparative
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classes of glucose-lowering drugs as second agents in patients
in whom metformin monotherapy fails (Online Fig. 5). Met-
formin therapy is the current evidence-based standard for
initial pharmacotherapy, but multiple medications are usu-
ally needed to maintain durable hemoglobin A1C control.
In this trial, participants would be randomized to second
stage treatment with incretin mimetics versus a thiazolidin-
edione versus a secretagogue, with insulin withheld for
third-line use.
Potential outcomes in each study could include noninva-
sive measures of atherosclerosis (e.g., coronary artery cal-
cium), progression of diabetes, quality of life, and satisfac-
tion with treatment. In light of unexpectedly higher rate of
total mortality in the more intensively treated group in
ACCORD, any early differences in subclinical disease
markers or surrogate outcomes ought to be confirmed by
subsequent assessments of clinical outcomes. Clinical car-
diovascular events (cardiac death, myocardial infarction, and
stroke) could be potential outcomes as well, although the
group recognized that potentially low event rates might
require large sample sizes and long follow-up. Depending
on the outcome and participant characteristics, this simple
trial could range from as few as 1,000 to 2,000 to as many
as 40,000 to 50,000 participants.
A registry could also be useful for post-marketing sur-
veillance of cardiovascular disease events among patients
prescribed drugs to treat diabetes.
Risk Stratification for Coronary Artery Disease
The current paradigm for prevention of coronary disease in
asymptomatic adults is based on individual risk assessment
using a standard risk predictor (such as the Framingham
Risk Score) and intervening with drug therapy among the
individuals identified as being at highest cardiovascular risk
(37). The optimal management for the patient at interme-
diate risk in this paradigm remains uncertain. Additional
risk stratification of individuals at intermediate cardiac risk,
with drug treatment of individuals with “positive markers,”
may substantially improve outcomes. There are many can-
didate risk markers that could be applied at the population
level, but coronary calcification on CT is quite promising, as
it provides high levels of incremental information and risk
reclassification. Consequently, the workshop participants
considered a large trial of coronary calcium screening among
individuals found to be at intermediate risk on conventional
evaluation (Online Fig. 6), with individuals found to have
elevated coronary calcium receiving intensive drug therapy
and lifestyle modification, and individuals without elevated
coronary calcium scores undergoing lifestyle modifications
alone. The trial could follow patients for up to 5 years, with
the primary outcome of major cardiac events. Secondary
outcomes could include quality of life, adherence to drug
and lifestyle management, cost, and cost-effectiveness. TThe current paradigm of individual risk assessment in-
cludes pharmacological therapy for those with elevated
Framingham risk scores, but most of the high-risk group
will not have a cardiovascular event in the subsequent 10
years. Additional testing of individuals with high Framing-
ham risk scores might identify a subgroup that would not
benefit sufficiently to justify lifelong pharmacological ther-
apy. Optimal management of these individuals might be
improved by imaging to document the severity of the
underlying disease process. The workshop participants also
suggest that a comprehensive evidence review and decision
modeling of the application of imaging the disease substrate
(e.g., by CT coronary angiography or coronary calcium
measurement) could help to further stratify risk and guide
therapy. This investigation would fit within the framework
outlined in Figure 1 and assist in determining the potential
alue of larger CER studies to address this question.
T Coronary Angiography
oronary angiography can now be performed noninvasively
ith recent generation CT scanners, and in several case
eries, CT angiography has demonstrated high sensitivity
nd good specificity when compared with invasive coronary
ngiography as a reference standard (38,39). These data
uggest that CT angiography may be very useful in the
valuation of patients with symptoms of coronary disease.
he effect of CT angiography on clinical outcomes is
ncertain, however, because visualization of coronary ob-
tructions may well lead to unnecessary or inappropriate
oronary revascularization, the value of detecting incidental
oncardiac findings is unknown, and the ionizing radiation
rom CT scanning may lead to adverse events. Conse-
uently, outcome-based studies of the comparative effec-
iveness of CT coronary angiography and alternative diag-
ostic strategies would address an important gap in the
vidence. The NHLBI is currently funding the PROMISE
Prospective Multicenter Imaging Study for the Evaluation
f Chest Pain) trial (NCT01174550), which is randomizing
ymptomatic patients suspected of having coronary artery
isease to either usual stress testing (functional) or CT
ngiography (anatomic).
Another study to address this IOM priority could be a
arge clinical trial of patients with symptoms suggestive of
oronary disease without high risk features, in which pa-
ients would be randomized to either invasive coronary
ngiography or to CT coronary angiography after a stress
est that had either inconclusive or “not high risk” results
Online Fig. 7). Patients in the invasive angiography arm of
he study would receive coronary revascularization according
o current usual care, whereas in the CT angiography arm of
he study, only patients with specific anatomic findings (left
ain disease, severe 3-vessel disease) would be recom-
ended to receive coronary revascularization (and invasive
ngiography if needed to further define coronary anatomy).
he primary endpoint of this trial study would be major
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stroke), for which the noninferiority of CT angiography
would be tested. Secondary endpoints could include quality
of life, cost, and cost-effectiveness, for which superiority of
CT angiography would be tested. The workshop partici-
pants suggest that any research infrastructure created for the
proposed trial could be used as an “advanced cardiovascular
imaging network” to conduct efficiently other CER studies
of imaging, as has been undertaken by the Canadian
Atherosclerosis Imaging Network and the Medical Imaging
Trials Network of Canada.
The workshop also identified a clinical registry of CT
coronary angiography procedures, ideally as an extension of
the ongoing National Cardiovascular Disease Registries
sponsored by the American College of Cardiology, as a
further opportunity to promote CER on this topic.
Conclusions
The recent recognition of the importance of comparative
effectiveness research places increasing emphasis on studies
that directly inform and improve patient care. The Work-
shop on Cardiovascular Comparative Effectiveness Research
was designed to propose approaches for the NHLBI to
consider, using both an overall framework for CER and
specific study designs as examples.
The approach to actionable research outlined by work-
shop participants implies a cycle of research and its appli-
cation (Fig. 1). The 4 important linked steps in this cycle
are: 1) the prospective articulation of research questions
based on identifying gaps in knowledge about optimal
patient care, incorporating input of stakeholders, including
patients; 2) the development of evidence by a variety of
research methods to address key evidence gaps; 3) applica-
tion of the evidence in practice guidelines and standards of
care; and 4) determination whether quality of care and
patient outcomes are improved.
Several important points follow logically from this vision,
beginning with consideration of a new research paradigm.
Following that, relationships can be created to identify
important research questions and infrastructure developed
to perform studies, such as large-scale registries and CER
trials, which can foster translation of research results into
practice. The training and development of CER researchers
and the creation of a culture of learning healthcare systems
are important steps in furthering CER. Finally, clear iden-
tification of evidence gaps and key questions will help guide
the performance of high-quality research.
The IOM has begun this process by identifying several
research priorities in cardiovascular disease. This workshop
has advanced this process by proposing research ideas to
address each of the 8 IOM priority areas. These range from
systematic reviews, to secondary analyses of existing data, to
registries, to large-scale clinical trials; each could add im-
portant evidence needed to improve patient care. The
workshop participants hope that these recommendationswill provide valuable information to investigators and fund-
ing agencies as they seek to advance the nation’s commit-
ment to cardiovascular comparative effectiveness research.
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